Revised free light chain reference intervals enhance risk stratification in monoclonal gammopathy of undetermined significance and reduce overdiagnosis

被引:0
|
作者
Cecilie Velsoe Maeng [1 ]
Sæmundur Rögnvaldsson [2 ]
Thórir Einarsson Long [3 ]
Christian Brieghel [4 ]
Emil Hermansen [3 ]
Carsten Utoft Niemann [5 ]
Kirsten Grønbæk [6 ]
Sigurður Yngvi Kristinsson [1 ]
Sigrún Thorsteinsdóttir [7 ]
机构
[1] Copenhagen University Hospital,Department of Hematology, Rigshospitalet
[2] University of Copenhagen,Biotech Research and Innovation Center (BRIC)
[3] University of Iceland,Faculty of Medicine
[4] Landspitali University Hospital,Department of Nephrology
[5] Skåne University Hospital,Department of Clinical Sciences
[6] Lund University,Department of Clinical Medicine, Faculty of Health and Medical Sciences
[7] Danish Cancer Institute,undefined
[8] University of Copenhagen,undefined
关键词
D O I
10.1038/s41408-025-01289-7
中图分类号
学科分类号
摘要
The free light chain (FLC) ratio is a critical part of risk stratification for monoclonal gammopathy of undetermined significance (MGUS). Recently, revised FLC reference intervals developed using the iStopMM cohort, accounting for age and renal function, have reduced the rate of abnormal findings. Here, we examine the implications of the revision in an independent Danish MGUS cohort. Of 6993 MGUS individuals, 2641 had an abnormal FLC ratio by the original intervals, of whom 844 (32%) were reclassified as normal using the revised intervals. Reclassified individuals had no significantly increased risk of progression compared to those with a normal FLC ratio (hazard ratio (HR): 1.07, 95% confidence interval (CI) 0.74–1.57). Those with an abnormal FLC ratio by the revised reference intervals had an increased risk of progression (HR 2.23, 95% CI 1.79–2.78). Using the revised reference intervals, 490 individuals (16%) were reclassified to low-risk from a higher risk group. These individuals had a similar progression risk compared to others in the low-risk group. The findings validate the revised FLC reference intervals, enhancing prognostic accuracy and improving risk stratification to accurately identify MGUS individuals at risk of progression while reducing unnecessary classifications as high-risk.
引用
收藏
相关论文
共 50 条
  • [1] Serum Free Light Chain Assays in the Risk Stratification of Monoclonal Gammopathy of Undetermined Significance: Results from a Pharmacoeconomic Evaluation
    Pratt, Guy
    Cranmer, Holly
    Almond, Christine
    Harding, Stephen
    Powner, Dale John
    Hughes, Richard Geir
    Cook, Mark
    BLOOD, 2015, 126 (23)
  • [2] Revised Definition of Free Light Chains in Serum and Light Chain Monoclonal Gammopathy of Undetermined Significance: Results of the Istopmm Study
    Long, Thorir Einarsson
    Rognvaldsson, Saemundur
    Thorsteinsdottir, Sigrun
    Sverrisdottir, Ingigerdur
    Eythorsson, Elias
    Indridason, Olafur
    Palsson, Runolfur
    Aspelund, Thor
    Vidarsson, Brynjar
    Onundarson, Pall T.
    Agnarsson, Bjarni
    Sigurdardottir, Margret
    Thorsteinsdottir, Ingunn
    Olafsson, Isleifur
    Thordardottir, Asdis Rosa
    Jonsson, Asbjorn
    Gislason, Gauti
    Olafsson, Andri
    Hultcrantz, Malin
    Durie, Brian G. M.
    Harding, Stephen J.
    Love, Thorvardur Jon
    Landgren, Ola
    Kristinsson, Sigurdur Y.
    BLOOD, 2023, 142
  • [3] SERUM FREE LIGHT CHAIN RATIO IS AN INDEPENDENT RISK FACTOR FOR PROGRESSION IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE
    Cherif, R.
    Eddine, B. Salah
    HAEMATOLOGICA, 2017, 102 : 774 - 774
  • [4] Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance
    Rajkumar, SV
    Kyle, RA
    Therneau, TM
    Melton, LJ
    Bradwell, AR
    Clark, RJ
    Larson, DR
    Plevak, MF
    Dispenzieri, A
    Katzmann, JA
    BLOOD, 2005, 106 (03) : 812 - 817
  • [5] Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance
    Rajkumar, SV
    Kyle, RA
    Therneau, TM
    Clark, RJ
    Bradwell, AR
    Melton, LJ
    Larson, DR
    Plevak, MF
    Katzmann, JA
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 127 (03) : 308 - 310
  • [6] Serum free light chain (FLC) ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance (MGUS)
    Katzmann, JA
    Kyle, RA
    Therneau, TM
    Melton, LJ
    Bradwell, AR
    Dispenzieri, A
    Rajkumar, SV
    CLINICA CHIMICA ACTA, 2005, 355 : S299 - S300
  • [7] Presence of monoclonal free light chains in serum predicts risk of progression in monoclonal gammopathy of undetermined significance (MGUS).
    Rajkumar, SV
    Kyle, RA
    Therneau, TM
    Bradwell, AR
    Melton, LJ
    Katzmann, JA
    BLOOD, 2003, 102 (11) : 935A - 935A
  • [8] Longitudinal assessment of established risk stratification models in patients with monoclonal gammopathy of undetermined significance
    Zuern, Kosima
    Hielscher, Thomas
    Werly, Annika
    Breitkreutz, Iris
    Sauer, Sandra
    Raab, Marc S.
    Mueller-Tidow, Carsten
    Goldschmidt, Hartmut
    Mai, Elias K.
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [9] Use of trabecular bone score for risk stratification of patients with monoclonal gammopathy of undetermined significance
    Sfeir, Jad G.
    Guzman, Tito D. Pena
    Bedatsova, Lucia
    Broski, Stephen M.
    Drake, Matthew T.
    BONE, 2020, 137
  • [10] Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma
    van de Donk, N. W. C. J.
    Mutis, T.
    Poddighe, P. J.
    Lokhorst, H. M.
    Zweegman, S.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2016, 38 : 110 - 122